Fastnet Equity Share Discussion Threads

[jacksonpollack] 11/4/2016 19:29

I know. But we won't learn anything from it.

[buffythebuffoon] 11/4/2016 19:02

It's mandatory.

Buffy

[jacksonpollack] 11/4/2016 16:45

Fastnet EGM booked for 18th April. What can they really say a day before the big change?

[ali47fish] 11/4/2016 16:11

hi jackson- but the ask price has come down to 2.65- i am hoping it goes down a little further then may be it makes sense to buy- dont you think?

[jacksonpollack] 11/4/2016 15:26

Boring. Should have just left it suspended. No one in their right mind is going to buy above 3p. Consolidation at 1 v 8 at 24p equates to 3p now. Looks like a backfired ploy to drop the share price before consolidation, IMO. Why else would they not stay suspended until 19th.

[bigwavedave] 10/4/2016 11:20

Sunday Times:

[alphabravo321] 10/4/2016 09:51

I have set up Amryt Pharma

[barnes4] 10/4/2016 09:45

Anyone fancy setting up an AMYT thread?

[buffythebuffoon] 10/4/2016 09:41

Pap, I wouldn't dream of disputing what you said, now you've confirmed that it was an actual dummy trade, as opposed to getting a non specific quote.

Of course, given the reason the topic was raised, £500's worth is, as you say, neither here nor there.

This discussion will be long forgotten when Amryt are the subject of a massive bidding battle between the world's largest bioparmaceutical companies.

Buffy

[barnes4] 10/4/2016 09:14

This will motor once the overhang clears up imo

[alphabravo321] 10/4/2016 09:04

Articles in both the Irish Sunday Business Post and Sunday Times about Amryt

[bigwavedave] 08/4/2016 14:47

papillon - I can confirm: firm price to buy below the mid. Not today (I haven't checked) but earlier this week.

[papillon] 08/4/2016 13:33

buffy, sorry old mate, I was right and you were wrong. I was quoted a price to buy £500's worth, by TDI, below 3p, on Wednesday on a T2 trade. All I had to do was press the buy button and the trade would have been final. I had over 10 seconds to do so. Instead I let the quote expire!!

I can't prove the above by the way; perhaps TDI took pity on a poor old pensioner!! LOL. Whether you believe me, or not, I'm not bothered.

PS. Whether you can buy at 3.025p, or 2.975p, it's no big deal on a £500 trade.

[papillon] 08/4/2016 13:23

buffythebuffoon
7 Apr'16 - 12:40 - 1274 of 1276 0 0


P.S. Pap, yes it was founded by CF, but it is/was a public company. It's not his money.

Buffy

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

Some of it would have been his money, buffy, if, as likely, he took part in FAST's initial placings when it was an O&G company. He was always likely to use that £10m to fund another of his start ups.

[bigwavedave] 08/4/2016 09:58

Amryt Pharmaceuticals’ Episalvan could have “significant commercial success”, says boss

Published on 8 Apr 2016

Joseph Wiley, chief executive elect of Amryt Pharmaceuticals, says the company is focused on treatment for rare orphan diseases.

Its lead product Episalvan, used to accelerate the healing of partial thickness wounds in adult, has already been approved in Europe and Wiley

[julesb9] 07/4/2016 19:40

Buffy - you are right - the announcement on the FAST website is just a notice of advice. Hopefully someone will put it properly on the site for all to read.jb9

[buffythebuffoon] 07/4/2016 12:40

P.S. Pap, yes it was founded by CF, but it is/was a public company. It's not his money.

Buffy

[buffythebuffoon] 07/4/2016 12:37

Update...I'm not confused, but I did misread the box on the home page. It was just advising of the presentation. I'll keep looking...

Buffy

[buffythebuffoon] 07/4/2016 12:35

Hi Joe,

I think we all agree on the lack of veracity in ADVFN quotes. You actually hit the nail on the head. What many people call dummy trades are not actual dummy trades, giving you a countdown to accept the offer.

There were no actual trades either, which led me to suspect you couldn't have bought below 3p. I guess there might have been a small number that got amalgamated in a bigger deal.

Of more interest... I went to look at the Amryt website for the presentation, and couldn't see one. The Fastnet Equity website is still up and running, and it's there I found the presentation.

That's a bit sloppy I thought. They knew when the LSE changeover was taking place...or am I confused... 🤔

Buffy

[bigwavedave] 07/4/2016 09:42

alphabravo: many thanks for the update.

[joesoap3] 07/4/2016 09:35

Buffy/Pap

It all depends on what you mean by a dummy trade. To me it is going to my online broker, selecting a number of shares and getting to the stage where your ACTUAL price is stated and I am given 15 secs to accept or reject it. So for me dummy trades are the exact price I can trade at whether I am buying or selling.

Pap is also correct in saying that buy and sell trades on ADVFN are notoriously wrong. They quote huge spreads and any thing below mid is a sell and anything above is a buy if its dead on mid price it is ?

A few seconds ago the sell price was 2.9375 and the buy price was 2.9948.

ADVFN are quoting 2.95/3.05 therefore any buy right now would show as a sell

[solomon] 07/4/2016 07:13

Thanks alphabravo, always good to get the views of someone who was at the scene. That's the great thing about these BB's.

[buffythebuffoon] 06/4/2016 20:50

Sorry Pap, it's you who are wrong. In fact, I doubt you have ever been so wrong. I've been investing for 40 years, and never use derivative data. I have level 2 - live prices and all trades that have gone through showing the volume and price and LSE trade codes. My friend also has a Bloomberg terminal and can verify my data. I once spent close to a year effectively as a market maker buying and selling the 'wrong side' side of mid price.

It's perhaps a novices mistake to think that dummy trades are actually indicative of the price you can trade at.

Feel free to quote a trade that went through as a buy below 3p though...

Buffy

[alphabravo321] 06/4/2016 20:45

I attended the FAST meeting in Dublin this evening, CF hosted the meeting with presentations from AMRYT CEO and CFO, both went into great detail on how the plan was put together and how it all came about. CEO Joe Wiley presented for approx 40 mins on the current products and potential future lines including the potential for near term licensing deals on existing and currently in development products. By far the star of the show is Episalvan and its potential use in the sure of certain types of wounds. They explained the approvals they have to date and the timelines for further clinical trials. The level of detail, organisation and the ease with which they discussed the fairly complex subject matter was impressive along with calibre of the team particularly the BOD. The presentation will be on the FAST web, it is very interesting reading particularly the market cap comparisons of similar companies with drugs at various stages of regulatory approval. I was happy before I went in, I am a lot happier now.My personal view is that they see several significant events in the 3-15 month range post RTO.